Azetidine-Driven SuFEx Macrocyclization and Bioconjugation

Chemoselective macrocyclization of unprotected peptides in aqueous media is essential for generating large screening libraries and advancing hit compounds toward therapeutic candidates; however, developing a broadly applicable strategy remains challenged by incomplete conversion, cross-reactivity with proteogenic side chains, and linker instability. Here, we report an azetidinedriven sulfur(VI) fluoride exchange (AzetSuFEx) platform to address these bottlenecks. Leveraging the high nucleophilicity of azetidine, SuFEx cyclization proceeds quantitatively across neutral and basic aqueous conditions, delivers stable linkers, and exhibits high chemoselectivity across 20 canonical amino acids. This selectivity enables a modular, one-pot multicyclization strategy by pairing AzetSuFEx with amine-, phenolate-, and thiolate-driven chemistries to cleanly construct diverse bicyclic architectures. Furthermore, extending AzetSuFEx to intermolecular systems overcomes the proximity constraints of conventional SuFEx bioconjugation, enabling multi-site functionalization under dilute conditions. By combining quantitative aqueous efficiency, proteogenic compatibility, and proximity-free bioconjugation, AzetSuFEx provides a practical platform for the discovery of macrocyclic peptide and bioconjugate therapeutics.

Authors

Institutions

Publication Details

Journal
ChemRxiv
Published
2026-11-12
DOI
https://doi.org/10.26434/chemrxiv.15012114/v1
Primary Topic
Chemical Synthesis and Analysis
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Azetidine-Driven SuFEx Macrocyclization and Bioconjugation

Qi Gao, Shuzhi Dong, Erwin G. Abucayon, Diego B. Diaz et al.
ChemRxiv
Chemical Synthesis and Analysis
preprint

Azetidine-Driven SuFEx Macrocyclization and Bioconjugation

Qi Gao, Shuzhi Dong, Erwin G. Abucayon, Diego B. Diaz, Tianxiong Mi, Xingjian Xu, Jack D. Scott, Yue Fu, Lijun Fan
preprint en

Abstract

Chemoselective macrocyclization of unprotected peptides in aqueous media is essential for generating large screening libraries and advancing hit compounds toward therapeutic candidates; however, developing a broadly applicable strategy remains challenged by incomplete conversion, cross-reactivity with proteogenic side chains, and linker instability. Here, we report an azetidinedriven sulfur(VI) fluoride exchange (AzetSuFEx) platform to address these bottlenecks. Leveraging the high nucleophilicity of azetidine, SuFEx cyclization proceeds quantitatively across neutral and basic aqueous conditions, delivers stable linkers, and exhibits high chemoselectivity across 20 canonical amino acids. This selectivity enables a modular, one-pot multicyclization strategy by pairing AzetSuFEx with amine-, phenolate-, and thiolate-driven chemistries to cleanly construct diverse bicyclic architectures. Furthermore, extending AzetSuFEx to intermolecular systems overcomes the proximity constraints of conventional SuFEx bioconjugation, enabling multi-site functionalization under dilute conditions. By combining quantitative aqueous efficiency, proteogenic compatibility, and proximity-free bioconjugation, AzetSuFEx provides a practical platform for the discovery of macrocyclic peptide and bioconjugate therapeutics.

ChemRxiv
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Chemical Synthesis and Analysis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon